Cholesterol Conversations: Mastering LDL Management in 2025

This thirty-minute podcast features discussion key screening guidelines, risk stratification, how to confront treatment barriers and overall best prevention therapies in the world of LDL cholesterol. 

Claiming Credit
Thank you for participating in this program. Once logged in, please click on "Take Course" on the right-hand side and your enrollment will be recorded. You will be prompted to complete evaluation and claim your credit on the following page.

Target Audience

This program has been designed to meet the needs of primary care physicians, nurses, family medicine practitioners, cardiologists and pharmacists. 

Learning Objectives

At the end of this activity, the learner should be better able to:

  • Describe current recommendations for LDL-C screening
  • Identify patients at increased cardiovascular disease risk based on LDL-C levels
  • Describe indications for initiation of statin and nonstatin therapies
  • Identify barriers to therapy initiation and options for resolution
  • Devise evidence-based strategies for optimal lipid management in primary prevention populations
Course summary
Available credit: 
  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 0.50 ANCC
    • 0.50 ANCC Pharmacology
  • 0.50 Participation
Course opens: 
03/31/2025
Course expires: 
03/30/2026
Rating: 
0

Boston University Chobanian & Avedisian School of Medicine Disclosure Policy
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. 

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.

Speakers Disclosures

Dr. Heather Johnson, MD, MS
Course Director

Disclosures: Dr. Johnson is a consultant for Amgen, Medtronic and Novartis. She is a consultant and a speaker for Esperion.

Viet Le, DMSc, MPAS, PA-C
Podcast Speaker

Disclosures: Dr. Le is on the advisory board for Amarin, Amgen, Bayer, Idorsia, Lexicon, Merck, Novartis and Pfizer. He also receives grant research support from Johnson & Johnson and Janssen, Kardi and AliveCor and Novartis. 

Off-Label Discussion: will not be included.

Accreditor Disclosures
The following planning committee members from Boston University Chobanian & Avedisian School of Medicine’s Office of Continuing Medical Education have no relevant financial relationships with ineligible companies:
Michael Burk, BS – Operations Manager; Deborah Whalen, APRN, MS, MBA - CNE Accreditation Reviewer.

John Fanikos, Rph, MBA
Pharmacy Advisor
Disclosures: Dr. Fanikos is a consultant for Anthos Therapeutics. He is also a speaker and consultant for Astra Zeneca and Pfizer.

 

Joint Accreditation

In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and Vasculearn Network. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 


Physician CME Hours
Boston University Chobanian & Avedisian School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Nursing Contact Hours: 0.5, all of which are eligible for pharmacology credits.

Pharmacist Contact Hours
This activity is approved for 0.5 CPE credit(s) under the ACPE universal activity number JA0000185-9999-25-024-H01-P. The activity is available for credit claiming through March 30, 2026.

 

Available Credit

  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 0.50 ANCC
    • 0.50 ANCC Pharmacology
  • 0.50 Participation
Please login or register to take this course.